Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy [Phase 1]
A Phase 1 clinical trial (GZ17-6.02) for advanced castration-resistant prostate cancer is currently recruiting after progression on anti-and…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 3]
A Phase III clinical trial evaluating BNT324 versus docetaxel in metastatic castration-resistant prostate cancer is listed as not yet recrui…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating cabozantinib in combination with nivolumab for metastatic castration-resistant prostate cancer is curren…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]
Early-phase clinical trial evaluating allogeneic anti-PSMA CAR-NK cells for metastatic castration-resistant prostate cancer is currently rec…
-
CLINICAL_TRIALS other · 2026-01-23Clinical Trial Update: Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A sequential Phase 1/2 clinical trial of 225Ac-LNC1011 for metastatic castration-resistant prostate cancer is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC) [EARLY_Phase 1]
This document describes an early-phase (Phase 1) exploratory clinical study evaluating the safety and potential efficacy of an allogeneic CA…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body [Phase 3]
This ClinicalTrials.gov entry outlines a Phase 3 trial evaluating whether adding carboplatin chemotherapy to cabazitaxel improves outcomes c…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating apalutamide with or without stereotactic body radiation therapy in castration-resistant prostate cancer completed, …
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) [Phase 1]
Phase 1 study ENGAGER-PSMA-01 evaluating JANX007 in metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies [Phase 1]
Phase 1 study update for DSB2455 assessing safety, tolerability, and activity in advanced HRD-associated cancers, including breast cancer, o…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) [Phase 1]
Phase 1 clinical trial evaluating autologous T cells engineered to target PSMA for men with metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer [Phase 1]
ClinicalTrials.gov entry indicates that HRS-5041-103 is a Phase 1 study assessing safety, tolerability, pharmacokinetics and efficacy in met…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Phase I Trial of A-CAR032 in Participants With mCRPC [Phase 1]
The document details a Phase I clinical trial of A-CAR032 for metastatic castration-resistant prostate cancer, with the study currently recr…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Efficacy of Ra-223 in PSMA PET Optimally Selected Patients [Phase 2]
Phase 2 trial update evaluating the efficacy of Radium-223 dichloride in PSMA PET–selected patients with castration-resistant, metastatic pr…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update on the Phase 1/Phase 2 safety and efficacy study of NUV-1511 in adults with advanced solid tumors, including HER2-nega…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study [Phase 2]
A Phase 2 clinical trial (SPECTRA) is evaluating whether supraphysiological androgen can enhance treatment activity in metastatic castration…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating a combination of difluoromethylornithine, high-dose testosterone, and enzalutamide for metastatic castration-resist…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
This clinical trial update reports termination of a study evaluating urokinase plasminogen activator receptor in abiraterone-treated castrat…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment [Phase 3]
Phase 3 trial evaluating Lu-177 labeled PSMA-targeted radioligand PNT2002 for metastatic castration-resistant prostate cancer after second-l…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors [Phase 1, Phase 2]
A first-in-human Phase 1/2 trial of JAB-8263 in adults with advanced tumors is currently recruiting across multiple cancer types including l…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel [Phase 2]
Phase 2 trial update evaluating abiraterone acetate with or without cabazitaxel and prednisone in metastatic castration-resistant prostate c…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC [Phase 2]
A Phase 2 trial evaluating the combination of cabozantinib with abiraterone in chemotherapy-naïve, bone-metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: 177Lu-HTK03170 in mCRPC With PSMA Positive Disease [Phase 1, Phase 2]
Trial update for a Phase 1/2 study of the radiopharmaceutical 177Lu-HTK03170 in metastatic castration-resistant prostate cancer; recruitment…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations [Phase 2]
A Phase 2 clinical trial update for CJNJ-67652000 in combination with prednisone to treat metastatic castration-resistant prostate cancer, i…
-
EMA approval · 2026-01-07EMA Authorised: Cabazitaxel Accord (cabazitaxel) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Cabazitaxel Accord for castration-resistant prostate cancer. The marketing authorization holder is …